摘要
目的:研究唑来膦酸和伊班膦酸钠治疗恶性肿瘤骨转移疼痛的药物经济学。方法:45例恶性肿瘤骨转移疼痛的患者随机分为两组,一组接受4mg唑来膦酸治疗,另一组接受4mg伊班膦酸钠治疗,比较两组患者首次住院双膦酸盐治疗的总费用、费用组成、疼痛缓解率、不良反应,进行药物经济学的费用-效果分析。结果:唑来膦酸组(n=23)总费用低于伊班膦酸钠组(n=22),分别为2 409.22元和3 903.64元(P<0.05);两组疼痛缓解有效率分别为78.3%和72.3%,无显著性差异(P>0.05);两组费用-效果比为31.75和53.99;不良反应发生率两组间无显著性差异(P>0.05)。结论:唑来膦酸是治疗恶性肿瘤骨转移的安全、有效、经济的药物。
Objective：To evaluate the pharmacoeconomics of zoledronate in treatment of metastatic bone pain of malignancy,compared with ibandronate.Methods： Total of 45 patients with metastatic bone pain of malignancy were randomly divided into two groups to receive 4 mg zoledronate or 4 mg ibandronate.Total cost,cost composition,pain relief response rate and side effects in the first treatment cycle were assessed.A cost-benefit analysis was conducted.Results： The total cost of zoledronate group（n=23）and ibandronate group（n=22） was 2409.22 yuan and 3903.64 yuan respectively（P0.05）.The pain relief rate was 78.3% and 72.3% respectively（P0.05）.The cost / effect of zoledronate group was lower than that of ibandronate group（31.75 vs 53.99）.There were no significant differences in incidence of adverse reactions（P0.05）.Conclusion： Zoledronate is a safe,efficient and economic alternative in the treatment of metastatic bone pain of malignancy.
出处
《现代肿瘤医学》
CAS
2011年第3期554-556,共3页
Journal of Modern Oncology
关键词
唑来膦酸
伊班膦酸
肿瘤转移
骨肿瘤
费用-效果分析
zoledronate
ibandronate
neoplasm metastasis
bone neoplasms
cost-benefit analysis
